Key facts
- It has raised $29.5M; the latest was Early Stage VC in Oct 2025.
- Notable investors include Qiming Venture Partners, Ennovation Ventures, Lujiazui Asset Management, Nanjing Jiangbei New Area Science and Technology Investment Group, Qiji Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Prime Lifescience
- ·The full record, as it builds
Funding rounds
No funding rounds for Prime Lifescience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prime Lifescience
Developer of a big data platform designed for life sciences. The company's platform is committed for digital clinical research and digital health community, enabling healthcare sector to have comprehensive medical solutions backed by big data.
- Sector
- Information Technology
- HQ
- Hangzhou, China
- Founded
- 2021
- Website
- primelifescience.com.cn/
- Ownership
- Privately Held (backing)
Prime Lifescience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prime Lifescience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prime Lifescience in its N-PORT filings yet. We sweep new filings monthly.